NAT2, N-acetyltransferase 2, 10

N. diseases: 311; N. variants: 10
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0236734
Disease: Caffeine related disorders
Caffeine related disorders
0.040 Biomarker group BEFREE Enzyme phenotyping was assessed in saliva and urine using caffeine metabolite ratios as follows: CYP1A2: 17X/137Χ (saliva) and CYP1A2: (AFMU+1U+1X)/17U, CYP2A6: 17U/(17U + 17X), XO: 1U/(1U+1X) and NAT2: AFMU/(AFMU+1U+1X) (urine). 31082462 2019
CUI: C0236734
Disease: Caffeine related disorders
Caffeine related disorders
0.040 Biomarker group BEFREE Enzyme phenotyping was assessed in saliva and urine using caffeine and paracetamol metabolite ratios as follows: CYP1A2: 17X/137X (saliva) and (AFMU+1U+1X)/17U, CYP2A6: 17U/(17U + 17X), XO: 1U/(1U+1X), NAT2: AFMU/(AFMU+1U+1X) and UGT1A1/1A6: glucuronidated/total paracetamol (urine). 30266316 2018
CUI: C0236734
Disease: Caffeine related disorders
Caffeine related disorders
0.040 GeneticVariation group BEFREE NAT2 genotype status did not apparently affect PX/CA ratio. 15022032 2004
CUI: C0236734
Disease: Caffeine related disorders
Caffeine related disorders
0.040 Biomarker group BEFREE Caffeine has also been shown to undergo 3-demethylation by CYP1A2, and it is further acetylated to 5-acetylamino-6-formylamino-3-methyluracil (AFMU) by the polymorphic NAT2. 1306111 1992